Show simple item record

dc.contributor.author Ladenstein R
dc.contributor.author Valteau-Couanet D
dc.contributor.author Brock P
dc.contributor.author Yaniv I
dc.contributor.author Castel V
dc.contributor.author Laureys G
dc.contributor.author Malis J
dc.contributor.author Papadakis V
dc.contributor.author Lacerda A
dc.contributor.author Ruud E
dc.contributor.author Kogner P
dc.contributor.author Garami, Miklós
dc.contributor.author Balwierz W
dc.contributor.author Schroeder H
dc.contributor.author Beck-Popovic M
dc.contributor.author Schreier G
dc.contributor.author Machin D
dc.contributor.author Pötschger U
dc.contributor.author Pearson A
dc.date.accessioned 2017-03-28T06:19:54Z
dc.date.available 2017-03-28T06:19:54Z
dc.date.issued 2010
dc.identifier 77955300179
dc.identifier.citation pagination=3516-3524; journalVolume=28; journalIssueNumber=21; journalTitle=JOURNAL OF CLINICAL ONCOLOGY;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/4121
dc.identifier.uri doi:10.1200/JCO.2009.27.3524
dc.description.abstract Purpose: To reduce the incidence of febrile neutropenia during rapid COJEC (cisplatin, vincristine, carboplatin, etoposide, and cyclophosphamide given in a rapid delivery schedule) induction. In the High-Risk Neuroblastoma-1 (HR-NBL1) trial, the International Society of Paediatric Oncology European Neuroblastoma Group (SIOPEN) randomly assigned patients to primary prophylactic (PP) versus symptom-triggered granulocyte colony-stimulating factor (GCSF; filgrastim). Patients and Methods: From May 2002 to November 2005, 239 patients in 16 countries were randomly assigned to receive or not receive PPGCSF. There were 144 boys with a median age of 3.1 years (range, 1 to 17 years) of whom 217 had International Neuroblastoma Staging System (INSS) stage 4 and 22 had stage 2 or 3 MYCN-amplified disease. The prophylactic arm received a single daily dose of 5 μg/kg GCSF, starting after each of the eight COJEC chemotherapy cycles and stopping 24 hours before the next cycle. Chemotherapy was administered every 10 days regardless of hematologic recovery, provided that infection was controlled. Results: The PPGCSF arm had significantly fewer febrile neutropenic episodes (P = .002), days with fever (P = .004), hospital days (P = .017), and antibiotic days (P = .001). Reported Common Toxicity Criteria (CTC) graded toxicity was also significantly reduced: infections per cycle (P = .002), fever (P < .001), severe leucopenia (P < .001), neutropenia (P < .001), mucositis (P = .002), nausea/vomiting (P = .045), and constipation (P = .008). Severe weight loss was reduced significantly by 50% (P = .013). Protocol compliance with the rapid induction schedule was also significantly better in the PPGCSF arm shown by shorter time to completion (P = .005). PPGCSF did not adversely affect response rates or success of peripheral-blood stem-cell harvest. Conclusion: Following these results, PPG-GSF was advised for all patients on rapid COJEC induction. © 2010 by American Society of Clinical Oncology.
dc.relation.ispartof urn:issn:0732-183X
dc.title Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: The European HR-NBL1/SIOPEN study
dc.type Journal Article
dc.date.updated 2017-03-14T14:23:13Z
dc.language.rfc3066 en
dc.identifier.mtmt 2031682
dc.identifier.wos 000280003700018
dc.contributor.department SE/AOK/K/II. Sz. Gyermekgyógyászati Klinika
dc.contributor.institution Semmelweis Egyetem


Files in this item

xmlui.dri2xhtml.METS-1.0.onlyFromAllowedIP

View/Open

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account